# A Trial of Remdesivir in Adults With Mild and Moderate COVID-19

> **NCT04252664** · PHASE3 · SUSPENDED · sponsor: **Capital Medical University** · enrollment: 308 (estimated)

## Conditions studied

- COVID-19
- SARS-CoV-2

## Interventions

- **DRUG:** Remdesivir
- **DRUG:** Remdesivir placebo

## Key facts

- **NCT ID:** NCT04252664
- **Lead sponsor:** Capital Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2020-02-12
- **Primary completion:** 2020-04-10
- **Final completion:** 2020-04-27
- **Target enrollment:** 308 (ESTIMATED)
- **Why stopped:** The epidemic of COVID-19 has been controlled well at present, no eligible patients can be recruitted.
- **Last updated:** 2020-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04252664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04252664, "A Trial of Remdesivir in Adults With Mild and Moderate COVID-19". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT04252664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*